Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Kristoff Muylle, P. Flamen, DJ Vugts, T Guiot, G Ghanem, N Meuleman, P Bourgeois, B Vanderlinden, GAMS van Dongen, Hendrik Everaert, M Vaes, D Bron

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1304-1314
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Publication statusPublished - 2015

Cite this